Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201210-05 Identification of candidate antibody molecules for inhibiting tumor angiogenesis(Oncology, Protein) [01.17.2013]


Development and Market Objectives

This project aims to develop optimized anti-angiogenic antibody lead substances through a three-step optimization process, using in vitro characterization and efficacy analysis to identify the final candidate antibodies.

Unmet Medical Need & Target Patients

Target patients: Patients with malignant tumors (inhibition of tumor angiogenesis). 
Unmet medical needs: Bevacizumab (Avastin®) is a U.S. Food and Drug Administration-approved anti-angiogenic therapeutic antibody currently used in clinics and occupied a market share of $590 million in 2012. However, Bevacizumab has the following limitations:

1) No significant efficacy as a single therapeutic agent.
2) Distinct side effects, including hypertension, proteinuria, bleeding, and gastrointestinal perforation.
3) Limitations of cancer therapy due to drug resistance issues.


Target validation and selection of anti-angiogenic antibody lead substances have been completed in previous studies. A three-step optimization process is currently under development.

Intellectual Property

U.S. provisional application: Targeted inhibition of angiogenesis by C-type lectin domain specific human antibodies against clec14a tumor endothelial cell marker 61/659,654
PCT application: Novel antibody specific for clec14a and uses thereof PCT/KR2012/008618 

Provisional application for the patent was lodged on June 14, 2012, with conversion to a PCT patent on October 19, 2012. The broad scope of rights includes the lead substances (antibodies) and epitopes, diagnostic and therapeutic compositions, kits, and methods for cancers and angiogenesis-related diseases

Competitive Advantages

1) Higher likelihood of development of a first-in-class drug through preclinical and clinical trials due to no development of therapeutic antibodies against the target molecule.

2) A broad range of intellectual property rights have already been secured, including development of antibodies and epitope identification. 

3) Superior anti-angiogenic treatment efficacy is expected through mechanisms distinct from the existing therapeutic antibody, Bevacizumab.

4) Developed antibodies are expected to have fewer side-effects because human antibodies have lower immunogenicity and exclusively target tumor blood vessel-specific antigens for specific targeted therapy.

5) Because the developed antibodies will be functional domain-specific antibodies that build on existing therapeutic antibodies and surpass their limitations, the time, effort, and costs associated with development are reduced. It is therefore expected that the wide range of industrial applications for the developed antibodies will enable a ripple effect superior to existing therapeutic antibodies.

6) Treatment can be applied to a variety of cancers through specific targeting of tumor blood vessels.

7) Treatment can be applied to several other diseases that require inhibition of angiogenesis, such as glaucoma and macular degeneration.

8) The antibodies under development can induce endocytosis through the cross-linking of antigen, underscoring an original technology for novel anti-cancer drug development that may be used as a platform technology for antibody-drug conjugates.



Research Period

Jan 01, 2013 ~ Jun. 30, 2014



Developmental Stage


Additional Information

Contact Information

Address Company Name: Scripps Korea Antibody Institute
WebSite Homepage: Contact Person: Jeong-Chi Park
E-mail: Contact: +82-33-250-8086

Related Projects

Related Project